Similar findings were recently reported from the ARIANES trial which also evaluated the rucaparib plus atezolizumab combination but in other tumour types [304, 305]: single-cell analyses performed sequentially on tumour biopsies of one responding gBRCA-mutant CRPC patient suggested that cGAS-STING activation occurred both in tumour cells and in some T-cell subpopulations, as suggested preclinically [15]. This evidence concerns the gene CGAS and neoplasm.